Longeveron (LGVN) Research & Development (2020 - 2026)
Longeveron (LGVN) posted quarterly Research & Development of $2.3 million for Q1 2026, down 7.79% year-over-year from $2.5 million in Q1 2025, and down 14.74% quarter-over-quarter from $2.7 million in Q4 2025.
Longeveron (LGVN) Research & Development (2020 - 2026) Analysis & Trends
Longeveron's Research & Development history runs 7 years deep, the most recent figure standing at $2.3 million for Q1 2026.
- In Q1 2026, Research & Development fell 7.79% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $11.8 million (up 40.48% YoY), while the FY2025 annual figure was $12.0 million, up 47.98% from the prior year.
- Research & Development for Q1 2026 stood at $2.3 million, down from $2.7 million in the prior quarter.
- The five-year high for Research & Development was $3.9 million in Q3 2025, with the low at $234000.0 in Q2 2022.
- The 5-year median for Research & Development is $2.2 million (2024), against an average of $2.2 million.
- The sharpest annual moves came in 2022 and 2023: Research & Development soared 880.0% in 2022, then slumped 33.93% in 2023.
- Longeveron's Research & Development stood at $3.3 million in 2022, then sank by 33.93% to $2.2 million in 2023, then dropped by 7.75% to $2.0 million in 2024, then surged by 36.75% to $2.7 million in 2025, then declined by 14.74% to $2.3 million in 2026.
- Business Quant data shows LGVN's Research & Development at $2.3 million in Q1 2026, $2.7 million in Q4 2025, and $3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 3.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.19 Mn |
| Mar 31, 2026 | 2.32 Mn |
| Dec 31, 2025 | 2.72 Mn |
| Sep 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 2.95 Mn |
| Mar 31, 2025 | 2.52 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 2.21 Mn |
| Jun 30, 2024 | 1.72 Mn |
| Mar 31, 2024 | 2.22 Mn |
| Dec 31, 2023 | 2.16 Mn |
| Sep 30, 2023 | 1.84 Mn |
| Jun 30, 2023 | 2.29 Mn |
| Mar 31, 2023 | 2.78 Mn |
| Dec 31, 2022 | 3.26 Mn |
| Sep 30, 2022 | 245,000.00 |
| Jun 30, 2022 | 234,000.00 |
| Mar 31, 2022 | 1.29 Mn |
| Dec 31, 2021 | -4.15 Mn |
| Sep 30, 2021 | 25,000.00 |